SCHEMBL21709277

SCHEMBL21709277

CC1(C)c2ccccc2-c2c(N(c3ccc(-c4ccccc4)cc3)c3nc(-c4ccccc4)nc4ccccc34)cccc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 8/20 0.47
CYP1A2 P05177 7/20 0.47
CYP3A4 P08684 7/20 0.47
CYP2C19 P33261 6/20 0.47
TSHR P16473 5/20 0.47
CYP2C9 P11712 5/20 0.47
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
GLA P06280 3/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 3/20 0.47
LMNA P02545 2/20 0.47
HIF1A Q16665 2/20 0.47
MAPT P10636 2/20 0.47
RECQL P46063 1/20 0.47
PDE5A O76074 3/20 0.44
ACP1 P24666 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ABCG2 Q9UNQ0 4/20 0.42
TP53 P04637 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21709404 0.95 CYP2D6 (0.44) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709402 0.92 CYP2D6 (0.42) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709395 0.91 CYP1A2 (0.42) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709414 0.90 MEN1 (0.45) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709489 0.90 MEN1 (0.45) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709321 0.90 MEN1 (0.45) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709425 0.90 MEN1 (0.45) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709398 0.89 CYP3A4 (0.39) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL17752684 0.89 ALDH1A1 (0.33) CYP2D6CYP1A2CYP3A4CYP2C19TSHR
SCHEMBL21709504 0.88 CYP2D6 (0.45) CYP2D6CYP1A2CYP3A4CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES MERCK PATENT GMBH (DE) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048207-A1 COMPOUNDS WITH ARYLAMINE STRUCTURES DDT, NAT1, INMT CYP2D6 24/4885CYP1A2 64/4885CYP3A4 108/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.